UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005543
Receipt number R000004825
Scientific Title The double blind study of the clinical effects of anti-cholinergic agent "imidafenadcin" for COPD patients.
Date of disclosure of the study information 2011/05/09
Last modified on 2012/05/01 19:38:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The double blind study of the clinical effects of anti-cholinergic agent "imidafenadcin" for COPD patients.

Acronym

The effects of imidafenacin for COPD.

Scientific Title

The double blind study of the clinical effects of anti-cholinergic agent "imidafenadcin" for COPD patients.

Scientific Title:Acronym

The effects of imidafenacin for COPD.

Region

Japan


Condition

Condition

COPD Chronic obstructive pulmonary disease

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate of clinical efficts and safety of imidafenacin, an anti-cholinergic agent for COPD patients.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

pulmonary function test

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Patients receive a single dose of Imidafenacin0.1mg, and then washout 7-14 days, patients receive a placebo.

Interventions/Control_2

Patients receive a placebo, and then washout 7-14 day, patients receive a single dose of Imidafenacin0.1mg.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Male and female Japanese patients aged 40 years or older with clinically diagnosed stable COPD.
FEV1.0/FVC<0.70
It does not matter for the stage of a disease.
A smoking history more than 10 pack years.
The patient who can acquire a document agreement from the person himself.

Key exclusion criteria

Patients were excluded from participation if they corresponds to a contraindicated matter of imidafenacin(urinary retention, bowel obstruction, paralytic ileus, glaucoma, myasthenica gravis).
The patient who is complicated with chronic respiratory desease except COPD.
Patient having allergy to anticholinergic agent.
The patient who has difficulty perform of the spirometry.
In addition, the patient who judged that the examination medical attendant was inappropriate.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiromasa Inoue

Organization

Graduate School of Medical and Dental Sciences Kagoshima University

Division name

Pulmonary Medicine

Zip code


Address

8-35-1 Sakuragaoka Kagoshima Japan

TEL

099-275-6481

Email



Public contact

Name of contact person

1st name
Middle name
Last name Ikkou higashimoto

Organization

Graduate School of Medical and Dental Sciences Kagoshima University

Division name

Pulmonary Medicine

Zip code


Address

8-35-1 Sakuragaoka Kagoshima Japan

TEL

099-275-6481

Homepage URL


Email



Sponsor or person

Institute

Graduate School of Medical and Dental Sciences Kagoshima University Pulmonary Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

鹿児島大学病院(鹿児島県)


Other administrative information

Date of disclosure of the study information

2011 Year 05 Month 09 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 03 Month 01 Day

Last follow-up date

2011 Year 12 Month 01 Day

Date of closure to data entry

2012 Year 03 Month 01 Day

Date trial data considered complete

2012 Year 03 Month 01 Day

Date analysis concluded

2012 Year 05 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 05 Month 02 Day

Last modified on

2012 Year 05 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004825


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name